--Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has granted Orphan-Drug Designation for TNX-2900* for the treatment of Prader-Willi syndrome.. “Orphan-Drug Designation by the FDA is an important milestone and further validates our efforts to investigate the...
This information caused a mild leap in the price, but then after that it went down again.... Sheesh. But the real question is will the company get an extension or get delisted?














